Pharma
-
Getty Images
Can AI crack pharma’s drug repurposing goldmine?
With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.
By Alivia Kaylor • May 29, 2026 -
Getty Images
Longevity science picks up steam in pharma
Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.
By Kelly Bilodeau • May 29, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Getty Images
Vertex’s Journavx made history, but left a void in the pain space
The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.
By Kelly Bilodeau • May 28, 2026 -
Permission granted by Bristol Myers Squibb
Q&AIn Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
By Jacob Bell • May 27, 2026 -
Getty Images
Can a chaotic FDA still deliver on faster drug development?
As leadership changes create more instability at the agency, here's what it'll take to keep speedier drug approvals on track.
By Kelly Bilodeau • May 26, 2026 -
Getty Images
Who’s winning pharma’s innovation race? The rankings are out.
While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.
By Meagan Parrish • May 22, 2026 -
Permission granted by American Biotech Innovation Alliance
Q&AChina’s biotech rise sparks new US industry alliance
The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.
By Kelly Bilodeau • May 21, 2026 -
Getty Images
Big Pharma is gambling on specialized R&D. Will it pay off?
Large pharma companies are taking bigger swings on fewer targets, which can be a risky strategy.
By Kelly Bilodeau • May 20, 2026 -
Courtesy of Regeneron Pharmaceuticals
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
By Ben Fidler • May 19, 2026 -
Getty Images
Race intensifies to lead next wave of obesity drugs as trial results loom
As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.
By Kelly Bilodeau • May 18, 2026 -
Alex Wong via Getty Images
Sanofi’s vaccine bump; the new FDA commish
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Sanofi’s vaccine bump ‘Sanofi’s vaccine sales are on the upswing this year, thanks to a boost from its newly acquired hepatitis ...
By PharmaVoice staff • May 15, 2026 -
Permission granted by Ovid Therapeutics
Q&AFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech
The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.
By Meagan Parrish • May 15, 2026 -
Getty Images
India’s pharma industry is going global. But can it catch up to China?
A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
By Kelly Bilodeau • May 13, 2026 -
Getty Images
Why the FDA’s push for real-time clinical trials could favor Big Pharma
The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.
By Alivia Kaylor • May 13, 2026 -
Permission granted by Sanofi
How tough is it getting for vaccine makers in the U.S.?
As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.
By Kelly Bilodeau • May 12, 2026 -
Permission granted by Curium
Sponsored by CuriumWhen reliability becomes patient care in nuclear medicine
Making reliability a clinical imperative can help scale theranostics beyond flagship centers.
By Renaud Dehareng, Group CEO, Curium • May 11, 2026 -
Getty Images
Biotech layoffs are easing, but is the worst over?
BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
By Kelly Bilodeau • May 8, 2026 -
Permission granted by Novo Nordisk
Novo hikes guidance on Wegovy pill’s fast sales start
Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity pill, the drugmaker said in its most recent earnings report.
By Kristin Jensen • May 7, 2026 -
Justin Sullivan via Getty Images
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.
By Kelly Bilodeau • May 7, 2026 -
Drew Angerer via Getty Images
A new company rises from the ashes of Purdue Pharma
Knoa Pharma will still sell the opioid medications that triggered a national crisis, but with guardrails.
By Kelly Bilodeau • May 6, 2026 -
Mario Tama via Getty Images
What’s at stake in Amgen’s showdown with the FDA?
The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the large pharma is digging its heels in.
By Meagan Parrish • May 5, 2026 -
Getty Images
Protein degraders gain speed as Arvinas scores landmark approval
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.
By Kelly Bilodeau • May 4, 2026 -
Getty Images
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
By Ben Fidler • April 30, 2026 -
Getty Images
Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
With many pharma companies focused on developing drugs that shed pounds, Biohaven is digging its heels into a clinical program based on an experimental myostatin inhibitor that builds muscle.
By Alivia Kaylor • April 29, 2026 -
Getty Images
As biosimilars gain US traction, patent thickets are under more scrutiny
A 10-year push for more biosimilars in the U.S. has led to a surge in copycat entrants, bringing more attention to the legal barriers.
By Michael Gibney • April 28, 2026
